ABSTRACT
Human MUC1 (Muc1 in animals) is an extensively O-glycosylated membrane-tethered mucin expressed on the surface of epithelial cells and some cells of the hematopoietic system. Recently, we showed that the hamster Muc1 on Chinese hamster ovary (CHO) cells served as a binding site for Pseudomonas aeruginosa (PA) through interaction between bacterial flagellin and the Muc1 ectodomain. Because CHO cells are known to produce an atypical pattern of protein glycosylation, we determined whether or not PA interacted with MUC1 endogenously expressed on human airway epithelial cells. Knock down of MUC1 expression in bronchial (NuLi-1) or alveolar (A549) epithelial cells by RNA interference significantly reduced PA binding to the cells. Conversely, over-expression of MUC1 in HEK293 cells increased bacterial adherence. By confocal microscopy, PA and MUC1 were colocalized on the surface of NuLi-1 cells. Taken together, these results confirm our previous observations in CHO cells and suggest that MUC1 serves as a binding site for PA on the surface of airway epithelial cells, which may have important consequences in the pathogenesis of PA lung infections.
INTRODUCTION
Pseudomonas aeruginosa (PA) is a Gramnegative bacterium that is commonly found in soil and water, but also is an opportunistic pathogen in patients who are predisposed to infection due to mechanical ventilation or immunosuppression, or who possess a homozygous mutant CFTR genotype. As a cause of ventilatorassociated pneumonia, PA has a higher mortality compared with other bacterial pathogens (1) . In the community, the incidence of PA respiratory tract infections is increasing in nursing home residents and patients with chronic obstructive pulmonary disease (2) . In addition, PA is the most prevalent chronic lung infection in patients with cystic fibrosis (CF) (3). Therefore, elucidating the mechanisms through which PA establishes and maintains lung colonization in the milieu of host inflammation will greatly contribute to understanding the etiopathogenesis of respiratory diseases.
A central dogma in the colonization of epithelial tissues by pathogens is that the interaction between microbial adhesins and their cognate host cell receptors is essential for establishment of infection (4) . Because PA is an important respiratory pathogen, major efforts have been directed at identifying the microbial and host factors relevant to initial bacterial attachment to airway cells. In this context, we noted with interest the prior reports that mucin glycoproteins purified from the sputum of CF patients were tightly bound to PA bacteria, suggesting that mucins act as bacterial receptors in the airways (5, 6) . However, these studies did not address the relationship between PA binding to the gel forming mucins and the host response to the bacteria at the molecular and cellular levels.
Our laboratory had previously characterized a primary hamster tracheal surface epithelial (TSE) cell culture system as a model to study the biochemistry and pharmacology of mucin secretion (7) . Mucin secretion was stimulated by neutrophil elastase, and biochemical and histochemical studies revealed that a significant portion of the released mucins was derived from the cell surface (8) . Because the only cell-associated mucin known at that time was MUC1, which had been cloned from a breast cancer cell line (9), we speculated that hamster TSE cells expressed Muc1. (By convention, MUC designates the human mucins and Muc refers to non-human homologues.) This was later confirmed by molecular cloning of the hamster Muc1 gene (10) and identification of Muc1 in the plasma membrane fraction and on the apical surface of the TSE cells (11) .
It is now well established that MUC1 is expressed on the apical surface of most airway epithelial cells, including goblet cells, ciliated cells, and types I and II alveolar pneumocytes (12, 13) . The deduced amino acid sequence of the MUC1 gene indicates a three domain structure of the protein with an extended, highly glycosylated NH 2 -terminal extracellular (EC) domain, a single pass transmembrane (TM) domain, and a COOHterminal cytoplasmic tail (CT) domain (9) . The MUC1 EC region contains a 20-amino acid tandem repeated segment with O-linked glycan moieties. The MUC1 CT domain is encoded by 72 amino acids including seven tyrosine residues, some of which are phosphorylated leading to activation of intracellular signal transduction cascades (14) . On the basis of these structural attributes, and the ability of CF mucins to bind to PA, we proposed that MUC1 serves as a receptor for PA in the airways (15) . In support of this hypothesis, it was observed that PA exhibited significantly greater adhesion to Chinese hamster ovary (CHO) cells stably expressing the cloned hamster Muc1 gene compared with cells transfected with the corresponding empty vector, suggesting a direct bacterial interaction with the glycosylated Muc1 ectodomain (16) . However, given that MUC1 over-expressed in CHO cells exhibits an uncommon pattern of O-glycosylation (17) , and the fact that the tandem repeats of human MUC1 (GSTAPPAHGVTSAPDTRPAP) and hamster Muc1 (GSSAPVTSSATNAPTTPVHS) only share 8 common residues (underlined), it was necessary to verify these observations using MUC1 expressed by human airway epithelial cells. In the current report, we show that MUC1 endogenously expressed by human bronchial and alveolar epithelial cells serves as a binding site for PA. These results are discussed in relation to MUC1's ability to counter-regulate the innate pro-inflammatory response, thereby preventing excessive inflammation during the latter stages of PA airway infection.
MATERIALS AND METHODS

Reagents
All reagents were from Sigma (St. Louis, MO) unless noted otherwise. Anti-MUC1 antibody (GP1.4) was from Biomeda (Foster City, CA).
A rabbit antiserum (CT33) against a synthetic peptide corresponding to the COOH-terminal 17 amino acids of MUC1 has been described (18, 19) . Horseradish peroxidase (HRP)-conjugated goat anti-mouse and goat anti-rabbit IgG antibodies were from KPL (Gaithersburg, MD). Alexa Fluor 488-conjugated rabbit anti-mouse IgG and Alexa Fluor 555-goat anti-mouse IgG were from Invitrogen (Carlsbad, CA). The MUC1-pcDNA3.1 expression plasmid was a generous gift from Dr. Sandra J. Gendler (Mayo Clinic, Scottsdale, AZ).
Cells
A549, an alveolar type II cell line derived from a lung adenocarcinoma (20) , was obtained from the American Type Culture Collection (Manassas, VA) and cultured as recommended. NuLi-1 cells, generously provided by Dr. Joseph Zabner (University of Iowa, Iowa City, IA), were derived from normal airway epithelium and immortalized by infection with HPV-16 E6/E7 (21) . The cells were cultured on collagen-coated plastic dishes (type VI, human placental; Sigma) in serum-free bronchial epithelial cell growth medium with supplements (Lonza/Cambrex Bioscience, Walkersville, MD). HEK293 cells stably expressing MUC1 in the pcDNA3.1 vector (MUC1-HEK293) or empty vector alone (pcDNA3.1-HEK293) have been described (19) and were cultured in DME medium, 10% FBS, antibiotics, and 800 µg/ml of G418 (Invitrogen).
MUC1 siRNA transfection
NuLi-1 (2.0 x 10 6 ) and A549 (1.0 x 10 6 ) cells were seeded in 12-or 24-well plates, incubated for 24 hr, and transfected with 5 or 20 nM of a MUC1 siRNA or a nontargeting control siRNA (D-001210, Dharmacon, Lafayette, CO) using 1.0 or 2.0 µl/well of Lipofectamine2000 (Invitrogen) according to the manufacturer's instructions.
The MUC1 siRNA consisted of a 21-bp sequence derived from the MUC1 gene (22) . Knock down of MUC1 mRNA and protein was confirmed by real time RT-PCR and Western blotting (23).
Pseudomonas aeruginosa
PA strain K (PAK) is a nonmucoid, piliated, and motile strain. PAO1 is a mucoid, piliated and motile strain. PAO1 expressing green fluorescent protein (GFP) (24) was kindly provided by Dr. Joanna B. Goldberg (University of Virginia, Charlottesville, VA). Bacteria were cultured overnight in LB broth supplemented with carbenicillin (60 µg/ml), washed with PBS, and cell concentrations determined spectrophotometrically using an OD 600 of 0.5 = 5.0 x 10 8 cells.
PA binding assays
Adhesion of PA to cells was performed by two assay procedures. The first utilized 35 S-labeled bacteria according to the method described (16) . Briefly, the cells were treated with the MUC1 siRNA or control siRNA as described above, washed twice with PBS, fixed for 10 min with 2.5% glutaraldehyde in PBS at room temperature, and washed three times with PBS. PAK were metabolically radiolabeled in sulfate-free M9 medium containing 10 µCi/ml Na 2 35 SO 4 (1,175 Ci/mmol, 100 mCi/ml, carrier-free; American Radiolabeled Chemicals, St. Louis, MO) for 16 hr at 37°C, washed twice, resuspended in PBS containing 2.0 mg/ml glucose, and quantified. Fixed cells were with various colony forming units (CFU) of PAK in 0.5 ml for 40 min at 37°C, washed three times with PBS, adhered bacteria were lysed with 1.0 ml of 2% sodium dodecyl sulfate, and radioactivity was measured by liquid scintillation counting. In the second procedure, GFP-PAO1 bacteria were incubated with fixed cells, unbound bacteria were removed by washing, and GFP fluorescence of adhered bacteria was detected by fluorescence-activated cell sorting (FACS).
FACS
The cells detached with 0.02% EDTA in PBS, were washed with PBS containing 1% FBS (wash buffer), resuspended in ice-cold wash buffer and either directly analyzed by FACS (for GFP-PAO1 binding assay) or incubated in wash buffer containing anti-MUC1 antibody (GP1.4; 1:100 dilution), and incubated for 30 min on ice. After washing, the cells were resuspended in ice-cold wash buffer containing Alexa Fluor 488-conjugated rabbit antimouse IgG secondary antibody (Invitrogen, 1:100) and incubated for 30 min on ice. The cells were washed, fixed with 1% paraformaldehyde at 4°C, and analyzed with a FACSCalibur instrument using BD FACS Comp software (BD Biosciences, Palo Alto, CA).
Immunofluorescence
NuLi-1 cells were grown on 8-well glass slides (Nalge Nunc, Naperville, IL), exposed to GFP-PAO1 for 10 min, the cells were washed 5 times with PBS, and fixed with 4% paraformaldehyde. The fixed cells were incubated with 5% goat serum (Abcam, Cambridge, MA) for 20 min, and sequentially incubated with GP1.4 antibody (1:100 in 1% goat serum) for 1 hr and Alexa Fluor 555-goat antimouse IgG (1:500 in 1% goat serum) for 30 min at room temperature. The cells were mounted with anti-fade reagent with DAPI (Invitrogen) and visualized with a Zeiss LSM 510 Meta confocal microscopy (Zeiss, Oberkochen, Germany) under 63X oil objective.
Statistical analysis
Differences between mean ± SEM values of various treatment groups were compared using the Student's t-test and considered significant at p < 0.05.
RESULTS
Knock down of MUC1 expression inhibits PA binding to human airway epithelial cells
Our prior results demonstrated that both PAK and PAO1 adhered to CHO cells stably transfected with a hamster Muc1 cDNA (CHO-Muc1) to a significantly greater extent compared with Muc1 non-expressing CHO cells (16) . To extend these studies to human airway epithelial cells endogenously expressing MUC1, we took the approach of blocking MUC1 expression by RNA interference and comparing PA binding to these cells with the corresponding MUC1 expressing cells. The MUC1 siRNA significantly reduced MUC1 mRNA levels ( Figure  1A ) and decreased protein expression both in cell lysates ( Figure 1B ) and on the surface ( Figure 1C 
Over-expression of MUC1 in HEK293 cells augments PA binding
To confirm the interaction between PA and MUC1 in an independent cell culture system, the GFP-PAO1 adherence assay was repeated using MUC1 nonexpressing HEK293 cells that had been stably transfected with a MUC1 cDNA, or empty pcDNA3.1 vector as a negative control. Confocal microscopy and Western blotting verified MUC1 expression in MUC1-HEK293, but not pcDNA3.1-HEK293 cells (Figures 5A and 5B) . Incubation of GFP-PAO1 with the cells for 1 hr followed by FACS analysis revealed approximately 3-fold increased bacterial adherence to MUC1-HEK293 cells compared with pcDNA3.1-HEK293 cells ( Figure 5C ).
Colocalization of PA and MUC1 on the cell surface
Laser scanning confocal microscopy was performed to confirm the localization of PA on the cell surface in the context of MUC1 expression. In nonpermeabilized NuLi-1 cells, MUC1 exhibited a staining pattern primarily localized to the cell surface ( Figure 6A ). 6 cells/well in 12-well plates, cultured for 24 hr, and transfected with 5 nM of a control siRNA or MUC1 siRNA using 2.0 µl/well of Lipofectamine2000. (A) MUC1 mRNA levels were quantified by real time RT-PCR at 72 hr post-transfection. Each bar represents the mean ± SEM values (n = 3). The Ct value was defined as the number of PCR cycles required for the specific fluorescence signal to exceed the detection threshold value set by the software installed in the iCycler. The levels of MUC1 transcripts were normalized to GAPDH transcripts using the -2 ∆∆Ct method. *, significantly decreased mRNA level (p < 0.05). Incubation of the cells with GFP-PAO1 for 30 minutes followed by extensive washing to remove unbound bacteria revealed the presence of PA bound to the cell surface ( Figure 6B ). Colocalization of GFP-PAO1 with MUC1 was observed after incubation of NuLi-1 cells with bacteria, upon both x-y imaging ( Figure 6D ) and z-stack imaging ( Figure 6E ). As a negative control, no GFP staining was observed with non-treated NuLi-1 cells (data not shown).
DISCUSSION
In this study, we demonstrated that knock down of MUC1 expression in NuLi-1 bronchial epithelial or A549 alveolar epithelial cells by RNA interference significantly reduced PA adherence to the cells. Overexpression of MUC1 in HEK293 cells increased PA binding to the cell surface.
Finally, by confocal microscopy, PA and MUC1 were colocalized to the surface of NuLi-1 cells. Taken together, these results suggest that MUC1 serves as a binding site for PA on the surface of human airway epithelial cells.
We considered the possibility that another PA receptor whose expression is modulated by MUC1 was responsible for bacterial adhesion. However, two lines of evidence are inconsistent with this hypothesis. First, PA binding to CHO cells expressing a Muc1 deletion mutant lacking the entire EC domain, but retaining the TM and CT regions of the molecule, was reduced to the level of that seen using Muc1 negative cells, indicating that the EC domain alone was necessary and sufficient for bacterial adhesion (16) . Second, treatment of A549 cells with PA bacteria or its purified flagellin induced tyrosine phosphorylation of the MUC1 CT (unpublished observations). The latter effect is reminiscent of the published studies demonstrating that treatment of cells expressing a CD8/MUC1 chimeric protein (containing the CD8 ectodomain and TM region fused to the MUC1 CT) with anti-CD8 antibody stimulated tyrosine phosphorylation of the CT (25, 26) .
PA is an opportunistic pathogen responsible for a wide range of pulmonary infections, one of the most debilitating being chronic infection and inflammation in CF patients. Transiently inspired PA are normally trapped by airway mucus and removed by mucociliary clearance, but pulmonary clearance is impaired in CF lungs. Although the reasons for impaired PA clearance in CF remain to be determined, several mechanisms have been proposed. These include increased bacterial adhesion to CF airway epithelial cells compared with non-CF cells (27, 28) , conversion of non-mucoid strains of PA that initially colonize the upper respiratory tract into mucoid alginate-producing variants (29) , mucus hypersecretion and plugging of the small airways (30) , over-activation of intracellular signaling pathways (31) , and an exaggerated host inflammatory response (32, 33) . DiMango and coworkers (34) demonstrated that asialo-GM1 glycolipids on the surface of airway epithelial cells were responsible for adhesion of PA. These authors also showed that airway epithelial cells from CF patients showed higher levels of asialo-GM1 suggesting a mechanism whereby PA colonization of CF lungs leads to chronic infection and inflammation as a result of increased bacterial adhesion early in the course of disease. It is important to note, however, that the molecular interactions between PA and respiratory epithelial cells are complex, involving multiple types of ligandreceptor contacts, and the relevance of any particular ligandreceptor interaction in bacterial adhesion is controversial (35) . For example, although several glycolipids, including asialo-GM1, have been suggested to act as co-receptors with TLR2 and TLR5 for flagellin (36, 37) , a subsequent study disputed this claim (38) .
A variety of PA-associated macromolecules are TLR agonists that could potentially serve to stimulate airway inflammation in CF (36) . However, only a limited number of studies have examined the TLR-mediated inflammatory response in the airways and, in particular, the role of PA-dependent inflammation in CF. In normal airways, TLR5 is expressed both by alveolar macrophages and epithelial cells (36, 39) and one study showed that a dominant TLR5 stop codon polymorphism abolished flagellin signaling that was associated with increased susceptibility to Legionnaires' disease (40) . Treatment of airway epithelial cells with PA flagellin induced TLR5 gene expression and mobilized the receptor from the basolateral to the apical surface of the cells (36) . Although CF lung cells have been shown to express equal amounts of TLR5 mRNA and protein compared with non-CF cells (41) , the effects of PA or flagellin on TLR5 expression and function in CF airways have not been reported. TLR signaling is activated by ligand-induced receptor aggregation, recruitment of cytoplasmic adaptor proteins (MyD88, TIRAP, TRIF) to the Toll/interleukin-1 receptor (TIR) intracellular domain, and activation of downstream kinases (IRAK, TRAF6) (42) . In the case of TLR5, binding of bacterial flagellin activated NF-kappaB, PI3K/Akt, and mitogen-activated protein kinases (36, (43) (44) (45) . Most of these downstream components also contribute to the innate immune response following ligation of other members of the TLR family with their cognate agonists. Indeed, our recent study using both in vivo and in vitro systems demonstrated that intracellular signaling cascades activated by TLR2, 3, 4, 5, 7, and 9 were suppressed by MUC1 (46).
In conclusion, based on the results presented in this report, as well those of prior publications, we suggest the following model of innate immune mechanisms in the airways following exposure to potential infectious agents such as PA. Under normal conditions, the small number of PA entering the lungs are trapped in airway surface liquid and quickly removed by mucociliary clearance and phagocytosis. If the numbers of PA increase, for example due to a predisposing condition such cystic fibrosis, TLRs on epithelial cells and resident macrophages are activated resulting in production of inflammatory mediators that promote leukocyte influx into the airways. We propose that the low level of MUC1 expression is insufficient to antagonize TLR signaling, but during ongoing inflammation the level of MUC1 expression increases by the direct effect of proinflammatory cytokines (47, 48) , as well as neutrophil elastase which is released by infiltrating neutrophils and up-regulates MUC1expression (23) . As a result of increased levels of MUC1, TLR-induced inflammation is inhibited, thus protecting the lung from excessive inflammation. Intuitively, one might expect that greater MUC1 protein expression may also increase PA adherence to airway epithelial cells through binding to the MUC1 ectodomain. We (49) and others (14) , however, have previously speculated that the presence of the extracellular cleavage site allows the MUC1 ectodomain to be shed from the cell surface, thereby releasing any bound constituents from the epithelium. Current studies in our laboratory are underway to elucidate the relative roles of the anti-inflammatory and bacterial binding-release functions of MUC1 in the airways.
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